Viracta Therapeutics (VIRX) Short Interest Ratio & Short Volume $0.0098 0.00 (0.00%) As of 07/25/2025 Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Viracta Therapeutics Short Interest DataViracta Therapeutics (VIRX) has a short interest of 14,300 shares. This marks a 76.54% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.0, indicating that it would take 0.0 days of the average trading volume of 1.11 million shares to cover all short positions.Current Short Interest14,300 sharesPrevious Short Interest8,100 sharesChange Vs. Previous Month+76.54%Dollar Volume Sold Short$137.28Short Interest Ratio0.0 Days to CoverLast Record DateJuly 15, 2025Outstanding Shares39,744,000 sharesPercentage of Shares Shorted0.04%Today's Trading Volume0 sharesAverage Trading Volume1,111,440 sharesToday's Volume Vs. Average0% Short Selling Viracta Therapeutics? Sign up to receive the latest short interest report for Viracta Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartVIRX Short Interest Over TimeVIRX Days to Cover Over TimeVIRX Percentage of Float Shorted Over Time Viracta Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/15/202514,300 shares $137.28 +76.5%N/A0 $0.01 6/30/20258,100 shares $134.46 -41.7%0.0%0 $0.02 6/15/202513,900 shares $243.25 -38.5%0.0%0.1 $0.02 5/31/202522,600 shares $413.58 -23.1%0.1%0.1 $0.02 5/15/202529,400 shares $514.50 -26.3%N/A0.2 $0.02 4/30/202539,900 shares $833.91 +405.1%N/A0.3 $0.02 4/15/20257,900 shares $132.72 -21.0%N/A0 $0.02 3/14/202528,200 shares $733.20 +108.9%N/A0 $0.03 2/14/202523,200 shares $396.72 -87.4%N/A0 $0.02 1/31/2025184,200 shares $27.91 thousand -25.1%0.7%0.1 $0.15 Get the Latest News and Ratings for VIRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Viracta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/2025246,000 shares $40.34 thousand -59.7%0.9%0.1 $0.16 12/31/2024609,900 shares $98.13 thousand -79.7%2.2%0.2 $0.16 12/15/20243,000,000 shares $608.10 thousand +89.9%10.7%1.4 $0.20 11/30/20241,580,000 shares $221.20 thousand -24.8%5.7%0.8 $0.14 11/15/20242,100,000 shares $317.10 thousand -21.9%7.5%2 $0.15 10/31/20242,690,000 shares $542.84 thousand +144.6%9.7%1.9 $0.20 10/15/20241,100,000 shares $241.56 thousand -17.3%4.0%1.7 $0.22 9/30/20241,330,000 shares $307.76 thousand +1.5%4.8%2.1 $0.23 9/15/20241,310,000 shares $328.81 thousand +4.0%4.7%2.1 $0.25 8/31/20241,260,000 shares $269.14 thousand -50.4%4.6%2.1 $0.21 8/15/20242,540,000 shares $885.19 thousand +178.5%9.2%4.8 $0.35 7/31/2024912,000 shares $436.85 thousand -6.4%3.3%8.5 $0.48 7/15/2024974,800 shares $517.62 thousand +35.2%3.5%10.7 $0.53 6/30/2024721,000 shares $392.01 thousand +1.7%2.6%7 $0.54 6/15/2024708,900 shares $477.66 thousand +3.8%2.6%6.7 $0.67 5/31/2024682,700 shares $477.89 thousand +2.1%2.5%6.3 $0.70 5/15/2024668,400 shares $561.46 thousand -4.4%2.4%6.5 $0.84 4/30/2024699,400 shares $573.23 thousand +1.9%2.5%6.3 $0.82 4/15/2024686,700 shares $535.63 thousand +6.0%2.5%6.2 $0.78 3/31/2024648,000 shares $660.96 thousand +2.2%2.4%6.8 $1.02 3/15/2024634,300 shares $631.76 thousand -7.1%2.3%5.7 $1.00 2/29/2024683,000 shares $556.65 thousand +0.6%2.5%5 $0.82 2/15/2024678,800 shares $433.75 thousand +4.5%2.5%4.5 $0.64 1/31/2024649,900 shares $370.44 thousand +0.4%2.4%4 $0.57 1/15/2024647,500 shares $384.23 thousand -1.9%2.4%3.8 $0.59 12/31/2023660,300 shares $376.37 thousand -14.9%2.5%3.8 $0.57 12/15/2023776,100 shares $361.97 thousand +19.3%2.9%4.6 $0.47 11/30/2023650,700 shares $316.89 thousand -8.2%2.4%4.9 $0.49 11/15/2023708,700 shares $425.50 thousand +3.0%2.6%7.3 $0.60 10/31/2023688,200 shares $424.28 thousand +12.0%2.6%7.5 $0.62Trump’s national nightmare is here (Ad)Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.Watch the National Emergency broadcast here 10/15/2023614,700 shares $436.44 thousand -2.7%2.3%7.6 $0.71 9/30/2023632,000 shares $657.28 thousand -4.3%2.4%7 $1.04 9/15/2023660,200 shares $838.45 thousand -5.3%2.5%7.8 $1.27 8/31/2023697,200 shares $1.00 million -4.4%2.6%6.8 $1.44 8/15/2023729,100 shares $947.83 thousand +5.2%2.7%4.5 $1.30 7/31/2023692,900 shares $1.07 million -3.9%2.6%2.8 $1.55 7/15/2023721,000 shares $1.05 million -1.0%2.7%2.9 $1.45 6/30/2023728,500 shares $1.03 million -7.8%2.8%3 $1.41 6/15/2023789,900 shares $1.26 million +14.0%3.0%3.3 $1.59 5/31/2023693,200 shares $921.96 thousand +12.4%2.6%3.2 $1.33 5/15/2023616,700 shares $807.88 thousand -2.2%2.3%3.4 $1.31 4/30/2023630,800 shares $813.73 thousand +2.0%2.4%8.4 $1.29 4/15/2023618,300 shares $902.72 thousand -2.5%2.3%9.6 $1.46 3/31/2023634,000 shares $1.01 million -19.5%2.4%8.4 $1.59 3/15/2023787,800 shares $1.33 million +51.7%3.0%8.7 $1.69 2/28/2023519,200 shares $882.64 thousand +3.9%2.0%4.9 $1.70 2/15/2023499,500 shares $994.01 thousand +5.6%1.9%4.5 $1.99 1/31/2023473,000 shares $983.84 thousand -2.5%1.8%3.8 $2.08 1/15/2023485,300 shares $1.10 million +3.2%1.8%3.9 $2.26 12/30/2022470,300 shares $686.64 thousand -15.1%1.8%3.8 $1.46 12/15/2022553,600 shares $1.06 million -0.1%2.1%5.2 $1.92 11/30/2022553,900 shares $1.29 million +7.3%2.1%5.1 $2.32 11/15/2022516,200 shares $1.50 million +8.8%2.0%4.8 $2.90 10/31/2022474,600 shares $1.87 million -9.6%1.9%4.7 $3.93 10/15/2022525,100 shares $1.97 million -4.4%2.0%5.1 $3.75 9/30/2022549,000 shares $2.34 million +9.3%2.1%5 $4.27 9/15/2022502,100 shares $2.81 million -3.9%2.0%2.6 $5.59 8/31/2022522,300 shares $2.12 million +0.6%2.0%2.3 $4.05 8/15/2022519,100 shares $2.29 million -8.2%2.0%2.2 $4.42 7/31/2022565,400 shares $1.88 million -16.1%1.9%2.2 $3.32 7/15/2022673,800 shares $2.99 million -32.5%2.3%2.5 $4.44 6/30/2022998,500 shares $3.87 million -48.5%3.4%3.2 $3.88 6/15/20221,940,000 shares $4.85 million -3.0%6.5%6.1 $2.50 5/31/20222,000,000 shares $4.24 million +8.7%6.7%8.1 $2.12 5/15/20221,840,000 shares $3.44 million -7.1%6.2%7.3 $1.87 4/30/20221,980,000 shares $5.05 million +16.5%6.7%6.2 $2.55 4/15/20221,700,000 shares $6.90 million +20.6%5.7%5.2 $4.06 3/31/20221,410,000 shares $6.71 million +20.5%4.8%4.7 $4.76 3/15/20221,170,000 shares $2.61 million +13.6%3.9%4.2 $2.23 2/28/20221,030,000 shares $2.81 million +7.8%3.5%3.5 $2.73 2/15/2022955,900 shares $2.98 million +26.0%3.2%3 $3.12 1/31/2022758,800 shares $2.03 million +5.5%2.7%2.9 $2.68 1/15/2022719,100 shares $2.28 million -15.4%2.5%3.3 $3.17 12/31/2021849,800 shares $3.10 million -2.7%3.0%3.7 $3.65 12/15/2021873,100 shares $3.12 million +30.4%3.1%4 $3.57 11/30/2021669,400 shares $3.09 million -24.3%2.4%3.8 $4.61 11/15/2021884,500 shares $4.93 million -15.0%3.1%5.5 $5.57 10/29/20211,040,000 shares $6.12 million -7.1%3.5%6.6 $5.88 10/15/20211,120,000 shares $7.25 million -1.8%3.8%7.5 $6.47 9/30/20211,140,000 shares $9.14 million -5.0%3.8%8.5 $8.02Trump’s national nightmare is here (Ad)Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.Watch the National Emergency broadcast here 9/15/20211,200,000 shares $10.08 million -9.1%4.0%5.5 $8.40 8/31/20211,320,000 shares $12.17 million -15.9%4.4%4.9 $9.22 8/13/20211,570,000 shares $16.11 million No Change5.3%5.7 $10.26 VIRX Short Interest - Frequently Asked Questions What is Viracta Therapeutics' current short interest? Short interest is the volume of Viracta Therapeutics shares that have been sold short but have not yet been closed out or covered. As of July 15th, investors have sold 14,300 shares of VIRX short. Learn More on Viracta Therapeutics' current short interest. Is Viracta Therapeutics' short interest increasing or decreasing? Viracta Therapeutics saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 14,300 shares, an increase of 76.5% from the previous total of 8,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Viracta Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Viracta Therapeutics: Scinai Immunotherapeutics Ltd. Sponsored ADR (70.43%), Onconetix, Inc. (34.27%), Shuttle Pharmaceuticals Holdings, Inc. (2.12%), Bio-Path Holdings, Inc. (0.13%), Sorrento Therapeutics, Inc. (0.65%), Evofem Biosciences, Inc. (0.00%), Salarius Pharmaceuticals, Inc. (10.59%), Oragenics, Inc. (7.10%), Petros Pharmaceuticals, Inc. (4.05%), Panbela Therapeutics, Inc. (0.00%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($5.11 billion), Charter Communications, Inc. ($4.76 billion), Reddit Inc. ($2.84 billion), SoFi Technologies, Inc. ($2.79 billion), Seagate Technology Holdings PLC ($2.79 billion), Live Nation Entertainment, Inc. ($2.67 billion), Rocket Lab Corporation ($2.49 billion), AST SpaceMobile, Inc. ($2.12 billion), Moderna, Inc. ($2.09 billion), and Omnicom Group Inc. ($2.04 billion). View all of the most shorted stocks. What does it mean to sell short Viracta Therapeutics stock? Short selling VIRX is an investing strategy that aims to generate trading profit from Viracta Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Viracta Therapeutics? A short squeeze for Viracta Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of VIRX, which in turn drives the price of the stock up even further. How often is Viracta Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VIRX, twice per month. The most recent reporting period available is July, 15 2025. More Short Interest Resources from MarketBeat Related Companies SCNI Short Squeeze ONCO Short Squeeze SHPH Short Squeeze BPTH Short Squeeze SRNE Short Squeeze EVFM Short Squeeze SLRX Short Squeeze OGEN Short Squeeze PTPI Short Squeeze PBLA Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:VIRX) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viracta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viracta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access